P626. Prevalence of different immune mediated inflammatory diseases in patients with inflammatory bowel disease. AQUILES study
I. Marín-Jiménez1, F. Gómez2, J.P. Gisbert3, J.L. Pérez-Calle4, M. Luján5, J. Gordillo6, I. Moral7, M. Andreu8, L. Cea Calvo9, R. García de Vicuña10, F. Vanaclocha11, C. Romero9, 1Gregorio Marañón Hospital, Spain, 2Reina Sofía Hospital, Spain, 3La Princesa Hospital & CIBEREHD, Spain, 4Alcorcón Foundation Hospital, Spain, 5Valencia General Hospital Consortium, Spain, 6Santa Creu i Sant Pau Hospital, Spain, 7Príncipe de Asturias Hospital, Spain, 8del Mar Hospital, Spain, 9Merck Sharp & Dohme de España, Spain, 10La Princesa Hospital IISP, Spain, 1112 de Octubre Hospital, Spain
Patients with inflammatory bowel disease (IBD) frequently show other immune mediated inflammatory diseases (IMID).
We describe the baseline prevalence of other IMID in patients with IBD recruited for the AQUILES study, a two year observational study that will evaluate the incidence of new diagnosis of IMID in patients with IBD, psoriasis or spondyloarthritis (SpA) recruited from IBD, Rheumatology, or Dermatology offices. For IBD patients, inclusion criteria were age ≥18 years-old and previous or new diagnosis of IBD.
478 patients with IBD were recruited (40.9 years-old [SD: 14.2]; 52.7% females; mean disease duration 3 years [IQR: 0–9]; history of familiar IBD: 12.6% and newly diagnosed IBD: 32.6%). The diagnoses were CD (58.2%), UC (40.4%) and indeterminate colitis (1.5%). The proportion of IBD patients with SpA at baseline was 9.8% (ankylosing spondylitis: 3.1%, enteropathic arthritis: 4.2%, undifferentiated SpA: 2.3%). The proportion with psoriasis was 2.5%, pyoderma gangrenosum was present in 2.1% and uveitis in 0.6%. There were no differences between men and women. SpA was more frequent in those with previous vs. de novo IBD (11.8% vs. 5.8%, p = 0.038) and, non-significantly, in those with familiar disease (17.2% vs. 9.4%, p = 0.070). IMID's were more frequent in CD (Table 1). In multivariate analysis including age, sex, IBD diagnosis, duration of disease, extra-intestinal findings and other IMID, SpA was associated to CD (OR: 2.0 [95% CI: 1.0–4.1] vs. UC) and disease duration ≥8 years (OR: 3.0 [1.5–6.3]) or 4–7 years (OR: 2.4 [1.0–5.7]), and psoriasis to CD (OR: 3.6 [0.8–16.4] vs. UC).
|Crohn's disease (n = 278)||Ulcerative colitis (n = 193)||p|
|Spondyloarthritis||36 (12.9%)||11 (5.7%)||0.010|
|Psoriasis||10 (3.6%)||2 (1.0%)||0.083|
|Pyoderma gangrenosum||8 (2.9%)||2 (1.0%)||0.068|
|Uveitis||2 (0.7%)||1 (0.5%)||0.794|
In patients with IBD recruited for the AQUILES study in Spain, the proportion of other IMIDs was higher than the known prevalence in general population of Spain. Psoriasis and SpA were more frequent in CD.